Niroula, Abhishek http://orcid.org/0000-0002-5904-0635
Sekar, Aswin
Murakami, Mark A.
Trinder, Mark
Agrawal, Mridul
Wong, Waihay J.
Bick, Alexander G.
Uddin, Md Mesbah http://orcid.org/0000-0003-1846-0411
Gibson, Christopher J. http://orcid.org/0000-0002-3700-5310
Griffin, Gabriel K.
Honigberg, Michael C. http://orcid.org/0000-0001-8630-5021
Zekavat, Seyedeh M.
Paruchuri, Kaavya
Natarajan, Pradeep http://orcid.org/0000-0001-8402-7435
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Funding for this research was provided by:
Howard Hughes Medical Institute
Fondation Leducq
Leukemia and Lymphoma Society
National Institutes of Health
Knut och Alice Wallenbergs Stiftelse (KAW2017.0436)
Damon Runyon Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32HL094301-07, R01HL142711, R01HL148050, R01HL151283, R01HL148565, T32HL007208-43)
Massachusetts General Hospital
Deutsche Forschungsgemeinschaft
Article History
Received: 16 February 2021
Accepted: 27 August 2021
First Online: 18 October 2021
Competing interests
: B.L.E. has received research funding from Celgene, Deerfield and Novartis and consulting fees from GRAIL. He serves on the scientific advisory boards for Skyhawk Therapeutics, Exo Therapeutics and Neomorph Therapeutics, none of which are directly related to the content of this paper. P.N. reports grant support from Amgen, Apple, AstraZeneca, Boston Scientific and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Genentech and Novartis and spousal employment at Vertex, all unrelated to the present work. G.K.G. reports affiliation to Moderna Therapeutics, which is unrelated to the present work. M.A. received consulting fees from German Accelerator Life Sciences and is a cofounder of iuvando Health and holds equity, all unrelated to the present work. All other authors declare no competing interests.